

Decree of the Chairman of the Egyptian Drug Authority No. (858) of 2025

The Chairman of the Egyptian Drug Authority,

Having reviewed:

- Law No. (127) of 1955 Regulating the Practice of the Pharmacy Profession, and its amendments;
- Law No. (182) of 1960 concerning the Combatting of Narcotic Drugs, the Regulation of Their Use and Trafficking Therein, and its amendments;
- Law No. (151) of 2019 concerning the Establishment of the Egyptian Drug Authority, and its Executive Regulations;
- The Single Convention on Narcotic Drugs of 1961;
- The Convention on Psychotropic Substances of 1971;
- The United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988;
- Ministerial Decree No. (172) of 2011 concerning the Regulation of Handling of Psychotropic Medicinal Products;
- Decree No. (455) of 2023 issued by the Chairman of the Egyptian Drug Authority concerning the formation of the Committee for the Evaluation, Study, and Review of Psychotropic Medicinal Products;
- The recommendations of the Committee for the Evaluation, Study, and Review of Psychotropic Medicinal Products established under Decree No. (455) of 2023 issued by the Chairman of the Egyptian Drug Authority, in its 10th session held on 5/3/2024 and its 19th session held on 21/5/2024;
- And in the public interest;

(Has decided)

(Article One)

-The classification status of medicinal products containing Phenobarbitone and Sodium shall be amended by listing them without concentration in Schedule Two of the schedules annexed to Ministerial Decree No. (172) of 2011, instead of their current listing under paragraph (E) of Schedule One.

(Article Two)

-A new clause shall be added to Article (6) of Ministerial Decree No. (172) of 2011 referred to above, stating the following:

(D) 600 packages of medicinal products containing Ketamine listed in Schedule One, including its salts, isomers, esters, ethers, and salts of all the foregoing, in the form of a nasal spray, shall be identified under the scientific name of the product without being limited to the trade name.

(Article Three)

-A new sub-item shall be added to Schedule One annexed to Ministerial Decree No. (172) of 2011, stating the following:

(C) bis: Medicinal products containing Ketamine and its salts, isomers, esters, ethers, and salts of all the foregoing.

(Article Four)

-Ketamine shall be deleted from item (C) of Schedule One annexed to Ministerial Decree No. (172) of 2011.

(Article Five)

-This Decree shall be published in the Egyptian Gazette and shall enter into force as of the day following the date of its publication, and all provisions contrary thereto shall be repealed.

Chairman of the Egyptian Drug Authority

Dr. Ali El Ghamrawy

Issued on: 25/12/2025



هَيْئَةُ الدَّوَاءِ الْمِصْرِيَّةِ